Tag: models

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

TKROBOTS introduces an AI-powered crypto quantitative trading platform with automated execution, wallet management, daily settlement records, and free trial access for new users.

MILWAUKEE, June 05, 2026 (GLOBE NEWSWIRE) -- Artisan Partners Asset Management Inc. (NYSE: APAM) today reported that its preliminary assets under management ("AUM") as of May 31, 2026 totaled $186.0 billion. Artisan Funds and Artisan Global Funds accounted for $92.3 billion of total firm AUM, while separate accounts and other AUM¹ accounted for $93.7 billion. During the period, Artisan was notified that a U.S. sub-advisory mandate representing approximately $5.7 billion of assets in the U.S. Value Team’s Value Equity strategy is expected to terminate in early June 2026.  The reduction in assets under management will have a muted impact on revenues given the nature of the mandate and its associated fees.